BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang SP, Wang Z, Wang LX, Liu SJ. AG490: An inhibitor of hepcidin expression in vivoWorld J Gastroenterol 2011; 17(45): 5032-5034 [PMID: 22174555 DOI: 10.3748/wjg.v17.i45.5032] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Conde Diez S, de las Cuevas Allende R, Conde García E. Estado actual del metabolismo del hierro: implicaciones clínicas y terapéuticas. Medicina Clínica 2017;148:218-24. [DOI: 10.1016/j.medcli.2016.10.047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Crielaard BJ, Lammers T, Rivella S. Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov 2017;16:400-23. [PMID: 28154410 DOI: 10.1038/nrd.2016.248] [Cited by in Crossref: 123] [Cited by in F6Publishing: 119] [Article Influence: 24.6] [Reference Citation Analysis]
3 Damm J, Harden LM, Gerstberger R, Roth J, Rummel C. The putative JAK-STAT inhibitor AG490 exacerbates LPS-fever, reduces sickness behavior, and alters the expression of pro- and anti-inflammatory genes in the rat brain. Neuropharmacology 2013;71:98-111. [DOI: 10.1016/j.neuropharm.2013.03.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
4 Vyoral D, Jiri Petrak. Therapeutic potential of hepcidin − the master regulator of iron metabolism. Pharmacological Research 2017;115:242-54. [DOI: 10.1016/j.phrs.2016.11.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
5 Hawula ZJ, Wallace DF, Subramaniam VN, Rishi G. Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis. Pharmaceuticals (Basel) 2019;12:E170. [PMID: 31775259 DOI: 10.3390/ph12040170] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
6 Gaffney-Stomberg E, McClung JP. Inflammation and diminished iron status: mechanisms and functional outcomes. Curr Opin Clin Nutr Metab Care. 2012;15:605-613. [PMID: 23075938 DOI: 10.1097/mco.0b013e328357f63b] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
7 Langer AL, Ginzburg YZ. Role of hepcidin-ferroportin axis in the pathophysiology, diagnosis, and treatment of anemia of chronic inflammation. Hemodial Int 2017;21 Suppl 1:S37-46. [PMID: 28328181 DOI: 10.1111/hdi.12543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
8 de Las Cuevas Allende R, Díaz de Entresotos L, Conde Díez S. Anaemia of chronic diseases: Pathophysiology, diagnosis and treatment. Med Clin (Barc) 2021;156:235-42. [PMID: 33358297 DOI: 10.1016/j.medcli.2020.07.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Kong WN, Gao G, Chang YZ. Hepcidin and sports anemia. Cell Biosci 2014;4:19. [PMID: 24731443 DOI: 10.1186/2045-3701-4-19] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
10 Liu J, Sun B, Yin H, Liu S. Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review. Medicine (Baltimore) 2016;95:e3150. [PMID: 27057839 DOI: 10.1097/MD.0000000000003150] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
11 Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol 2014;5:86. [PMID: 24808863 DOI: 10.3389/fphar.2014.00086] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 9.5] [Reference Citation Analysis]
12 Murawska N, Fabisiak A, Fichna J. Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: Pathophysiology, Diagnosis, and Treatment. Inflamm Bowel Dis. 2016;22:1198-1208. [PMID: 26818422 DOI: 10.1097/mib.0000000000000648] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 6.8] [Reference Citation Analysis]
13 Angmo S, Rana S, Yadav K, Sandhir R, Singhal NK. Novel Liposome Eencapsulated Guanosine Di Phosphate based Therapeutic Target against Anemia of Inflammation. Sci Rep 2018;8:17684. [PMID: 30523271 DOI: 10.1038/s41598-018-35992-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Guo W, Zhang S, Chen Y, Zhang D, Yuan L, Cong H, Liu S. An important role of the hepcidin-ferroportin signaling in affecting tumor growth and metastasis. Acta Biochim Biophys Sin (Shanghai) 2015;47:703-15. [PMID: 26201356 DOI: 10.1093/abbs/gmv063] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
15 Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 2013;98:1667-76. [PMID: 24186312 DOI: 10.3324/haematol.2013.084624] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
16 Reichert CO, da Cunha J, Levy D, Maselli LMF, Bydlowski SP, Spada C. Hepcidin: Homeostasis and Diseases Related to Iron Metabolism. Acta Haematol 2017;137:220-36. [DOI: 10.1159/000471838] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
17 Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets 2019;23:407-21. [PMID: 30907175 DOI: 10.1080/14728222.2019.1599358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
18 Ginzburg YZ. Hepcidin-ferroportin axis in health and disease. Vitam Horm 2019;110:17-45. [PMID: 30798811 DOI: 10.1016/bs.vh.2019.01.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
19 Blanchette NL, Manz DH, Torti FM, Torti SV. Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Rev Hematol 2016;9:169-86. [PMID: 26669208 DOI: 10.1586/17474086.2016.1124757] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
20 Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial Activity of Mesenchymal Stem Cells: Current Status and New Perspectives of Antimicrobial Peptide-Based Therapies. Front Immunol 2017;8:339. [PMID: 28424688 DOI: 10.3389/fimmu.2017.00339] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 18.8] [Reference Citation Analysis]
21 Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest 2013;123:2337-43. [PMID: 23722909 DOI: 10.1172/JCI67225] [Cited by in Crossref: 123] [Cited by in F6Publishing: 56] [Article Influence: 13.7] [Reference Citation Analysis]
22 Katsarou A, Pantopoulos K. Hepcidin Therapeutics. Pharmaceuticals (Basel) 2018;11:E127. [PMID: 30469435 DOI: 10.3390/ph11040127] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
23 Sebastiani G, Wilkinson N, Pantopoulos K. Pharmacological Targeting of the Hepcidin/Ferroportin Axis. Front Pharmacol 2016;7:160. [PMID: 27445804 DOI: 10.3389/fphar.2016.00160] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
24 Rana S, Prabhakar N. Iron disorders and hepcidin. Clin Chim Acta 2021;523:454-68. [PMID: 34755647 DOI: 10.1016/j.cca.2021.10.032] [Reference Citation Analysis]
25 Zhang F, Zhao P, Qian Z, Zhong M. Central Nervous System Inflammation Induced by Lipopolysaccharide Up-Regulates Hepatic Hepcidin Expression by Activating the IL-6/JAK2/STAT3 Pathway in Mice. Front Nutr 2021;8:649640. [PMID: 33869267 DOI: 10.3389/fnut.2021.649640] [Reference Citation Analysis]